Microbix Biosystems Inc.

268 articles with Microbix Biosystems Inc.

• Microbix & Copan Italia Execute Strategic AgreementFor FLOQ devices & QAPs Co-branding, IP licensing, Co-marketing, Purchase and Supply

  12/21/2020

  Microbix Biosystems Inc., a life sciences innovator and exporter, and Copan Italia S.p.A., the global leader in specimen collection technologies, announce their execution of a strategic agreement in relation to Microbix’s quality assessment products and Copan’s flocked devices.

• Microbix Reports Results for Fiscal 2020Full-Year Sales of $10.5 Million, QAPs Sales Grow by 41%

  12/18/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its 2020 fiscal year (“2020”) and fourth quarter (“Q4”) ended September 30, 2020, with continued progress toward its operational goals.

• Microbix Presenting Product Results at AACCReporting on Test-Workflow Controls for Important Sexually-Transmitted Infections

  12/15/2020

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces it has been invited to present about the performance of two types of its test-workflow Quality Assessment Products (QAPs™) at the 2020 virtual Scientific Meeting and Clinical Lab Expo of the American Association of Clinical Chemistry (AACC) taking place December 13-17, 2020.

• Microbix Announces Addition to Board of Directors Appointment of Anthony J. Giovinazzo, Accomplished Life Sciences Leader

  12/7/2020

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces that Mr. Anthony J. Giovinazzo, an accomplished leader in the international life sciences industry, has joined its Board of Directors.

• Microbix Discloses New Products, Sales and CapacitySales of QAPs™ kits to help qualify multi-pathogen respiratory test systems

  10/29/2020

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the availability and initial material sales of “onboarding” kits of its quality assessment products (QAPs™), designed to help testing sites with the successful installation and qualification of multi-pathogen respiratory testing systems.

• Microbix Creates Further COVID-19 Quality Assessment ProductsQAPs™ to support accuracy of COVID-19 antigen-test workflows

  10/20/2020

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces its creation, external verification, initial sales, and first shipments of a new class of quality assessment products to help implement or ensure workflow accuracy of antigen-based tests for the virus causing COVID-19 disease.

• Microbix Launches New STI-Related Quality Assessment Products

  10/15/2020

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces its creation, external verification, and registration of new quality assessment products to help ensure the accuracy of workflows at labs conducting nucleic acid testing for sexually-transmitted Mycoplasma genitalium infections.

• Ontario Helps Microbix Ensure Provincial COVID Testing CapacityGrant of $1.45 Million for Ontario-based Production of Critical Test Reagents

  10/13/2020

  Microbix Biosystems Inc., a life sciences innovator and exporter, is pleased to announce the execution of a grant agreement with the Ontario Together Fund of the Ministry of Economic Development, Job Creation and Trade.

• Microbix Presenting COVID-19 Product Results to IndustryAbstract Reports Multi-Platform Utility of IVD SARS CoV-2 Lab Workflow Control

  9/22/2020

  Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix ® ), an award-winning life sciences innovator and exporter, announces it is has been invited to present about the performance of its COVID-19 in-vitro diagnostics (IVD) quality assessment products at “ECCVID,” a virtual conference on Coronavirus disease organized by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), taking place September 23-25, 2020

• Microbix Announces Extension of Warrant Expiry DatesApplies for 12-month Term Extension of October 2015 and October 2017 Warrants

  9/17/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces it has applied to the TSX to extend the term of an aggregate of 7,413,052 common share purchase warrants which were issued in connection with Microbix’s October, 2015 and October, 2017 private placement financings.

• Microbix Announces Board Changes

  9/15/2020

  William J. Gastle retiring, Martin Marino nominated to become Independent Chairman

• Microbix’s REDx™ Controls Attain Australian TGA RegistrationEnables Use of COVID-19 and HPV Products by Australian Clinical Labs

  9/10/2020

  MISSISSAUGA, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix ® ), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs™) – TGA registration of these REDx™ Controls & REDx™FLOQ ® products by Microbix’s distributor, R-Biopharm, enables it to offer these workflow contro

• Microbix Reports Results for Q3 Fiscal 2020Year-Over-Year QAPs Sales Growth of 141% for Q3

  8/14/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, reports results for its third quarter and year to date fiscal 2020 ended June 30, 2020, with an increase of 141% in sales of Quality Assessment products.

• Microbix Shares Become Available for U.S. InvestorsOTC Markets Listing and DTC Electronic Clearance Eligibility

  7/14/2020

  Microbix Biosystems Inc. announces that it has completed two processes to make its common shares available for U.S. investors to buy and sell; the listing of its common shares on the OTCQB platform under the ticker symbol MBXBF, and approval for electronic clearance and settlements of trades by way of DTC Eligibility.

• Microbix COVID-19 QAPs Attain EU “CE mark” RegistrationEnables Usage of SARS-CoV-2 Controls by Clinical Labs across Europe

  6/5/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, is pleased to announce the attainment of European Union “CE mark” registration for its SARS-CoV-2 quality assessment products – CE mark registration enables Microbix’s network of distributors that now covers 18 EU countries to immediately begin providing these products to clinical laboratories across the EU.

• Microbix Announces Quality Products Distribution AgreementAppointment of Alpha-Tec Systems, Inc. for the United States

  6/4/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces the appointment of Alpha-Tec Systems, Inc., a Calibre Scientific Inc. firm, as distributor of its Quality Assessment Products for the United States.

• Microbix Engaged to Develop & Supply Custom QAPsInstrument-Specific Controls to Support Rapid Tests for Viral Respiratory Pathogens

  6/1/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has been engaged to develop and supply custom quality assessment products (QAPs™) to support the registration and sales of a new point-of-care instrument and its tests for viral respiratory pathogens.

• Microbix Expanding QAPs™ Production CapacityBuild-out to Support Tenfold Increase Now Underway

  5/27/2020

  Microbix Biosystems Inc. announces that it has begun a build-out of its second facility that is initially intended to support a tenfold increase of production capacity for its QAPs™ quality assessment products – which support the accuracy of clinical laboratory testing including, but not limited to, support for tests for the SARS-CoV-2 virus causing COVID-19 disease.

• Microbix Achieves Full Utilization of its Bioreactors

  5/19/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces that it has achieved full utilization of the six bioreactor units it installed for manufacturing the “antigens” which are at the core of immunoassays that establish exposure or immunity to the Rubella virus, the cause of German Measles.

• Microbix Announces Quality Products Distribution AgreementAppointment of R-Biopharm AG for 11 Countries

  5/15/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of R-Biopharm AG (R-Biopharm) as distributor of its Quality Assessment Products (QAPs™) in eleven (11) countries. Under an agreement between the parties, R-Biopharm has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Australia, Belgium, Canada, France, Germany, Luxembourg, Ne